Agenda
October 8, 2026
Registration will remain open throughout the conference.
Our summit will kick off with a fireside chat between Eli Lilly’s Gregg Spivey and Potato’s Nick Edwards who will provide a look at where AI is having meaningful impact today — and how it could change the speed, efficiency and execution of drug development.
Join our speakers as they delve into how AI is being put to work across biotech — from R&D and clinical development to infrastructure and enterprise operations — and where it has the greatest potential to compress timelines and change how companies get work done. Featuring our new format, this intensive session will combine expert insights, a substantive discussion between industry leaders, and audience Q&A, giving attendees the opportunity to explore this key issue through a more nuanced lens.
Jacob Berlin, Ph.D.
Co-Founder & CEO, Terray Therapeutics
Nellie Brutocao
Partner, Wilson Sonsini
Pantea Khodami
Worldwide Head: Life Sciences and Precision Medicine – Solutions & Strategy, Amazon Web Services (AWS)
Tyrone Lam
Chief Business Officer, GATC Health
Alon Wellner, Ph.D.
Co-Founder & Chief Innovation Officer, Aureka Biotechnologies
This conversation will explore how CEOs are navigating the changing landscape and how U.S. companies can engage globally while protecting and strengthening their competitive advantage.
Industry CEOs won’t want to miss our keynote session with Harpreet Singh, M.D., chief medical officer at Precision for Medicine, who will share her perspective on how regulatory systems need to evolve and what U.S. biopharma companies must do to remain globally competitive.
This conversation will explore where the U.S. is losing speed and efficiency, how clinical development and regulatory systems need to evolve, and what biotech leaders can do to compete in an increasingly global innovation landscape.
Gary Firestein, M.D.
Senior Associate Vice Chancellor for Health Sciences & Distinguished Professor of Medicine, UC San Diego
Dave Hanaman
President & Co-Founder, Curavit
Ann Lucchesi
Regulatory Affairs Principal Consultant, LUCORE Regulatory Consulting
Mani Mohindru, Ph.D.
President & CEO, Cardiff Oncology
This fireside will explore how CEOs can think creatively about financing innovation—combining traditional investment with government funding, philanthropy and other non-dilutive sources to keep promising technologies moving forward. Drawing on Exthymic’s experience securing significant ARPA-H funding, the conversation will offer a candid look at navigating funding gaps and building a capital strategy around the needs of the science.
Don’t miss our engaging and interactive session with industry experts who will share invaluable insights, trends and strategies. Join the conversation, interact with key players and gain a unique perspective of the current life science landscape through the lens of venture capital.
Arun Pores Fernando, Ph.D.
Senior Director, Lilly Ventures, Eli Lilly
Ida Khodami
Investor, Tech/Bio
Pascal Krotee, Ph.D.
Principal, RiverVest Venture Partners
Arun Thottumkara, Ph.D.
Senior Director, Drug Maker, Chemistry, Curie.Bio
Asish Xavier, Ph.D.
Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC
Unwind from a day of thought-provoking panel discussions and fireside chats and join fellow executives in continued conversations while you enjoy delicious refreshments. This reception provides an excellent opportunity to network with summit attendees and speakers one final time before the conference concludes.